Genelux Investor Presentation Deck

Demonstrated Deep and Durable Tumor Shrinkage Tumor Shrinkage Key Clinical Takeaways Refractory patients performed as well as resistant patients Tumor Shrinkage Overall, 86% of PRROC patients showed tumor reduction, with 91% of Platinum-refractory patients showing tumor reduction ● Four patients had 100% reduction target lesions (two with confirmed CR), including two platinum-refractory patients Duration of Response (DOR) DOR of 7.6 Months in all platinum- ● Resistant patients DOR of 8.0 Months in platinum- refractory patients GENELUX Best change of target lesions from baseline (%) 60 Change of target lesion size (% change of SLD) 40 20 O -20 -40 -60 -80 -100 15A-18 33 15B-09 15B-19 120 15A-19 15A-27 32 180 100 80 60 40 20 0 -20 -40 -30% partial response -60 -80 -100 Duration of Response 15A-38 15B-18 platinum-resistant platinum-refractory 240 15A-06 Time (days) 300 15A-30 15A-23 15B-01 15A-29 15A-05 70 360 15A-37 15B-17 PD SD 15A-22 Objective Response (CR or PR) 420 -30% partial response 15A-16 24 58 81 62 132 19 48 46 45 Baseline tumor burden as Sum of Longest Diameter of target lesions (mm) 65 15A-09 480 15A-25 83 15B-15 540 82 15A-31 12 15A-34 14

View entire presentation